Denosumab Treatment Outcomes for Elderly Hip Fracture Patients

379 elderly patients with primary osteoporotic hip fractures were observed over three years to assess denosumab treatment effects. The retrospective study, conducted by Yuzhu Wang, analyzed data from Zhongshan Hospital, Fudan University, collected between January 2020 and December 2021. It compares refracture and mortality rates between a denosumab treatment group and a control group.

Use Cases

• Compare refracture rates (13.4% vs. 38.3%) and mortality hazard ratios (HR=0.45) between denosumab and control groups.
• Analyze treatment effects stratified by patient age subgroups (65-84 years and 85+ years).
• Validate study findings using statistical methods like Propensity Score Matching (PSM) and Inverse Probability of Treatment Weighting (IPTW) mentioned in the description.

Strengths

• Study includes 379 patient records with a three-year observation period.
• Analysis employs rigorous statistical adjustment methods (PSM, IPTW) to control for group differences.
• Results show statistically significant reductions in refracture (SHR=0.37) and mortality (HR=0.45) for the treatment group.

Limitations

• Sample size of 379 patients is relatively small for broad generalization of findings.
• Data is from a single hospital (Zhongshan Hospital), which may introduce geographic or institutional bias.
• The underlying patient-level data (rows, columns) is not directly accessible in the provided DOCX/TIF files, limiting direct computational analysis.

Provenance

Source

Zhongshan Hospital, Fudan University.

Collection Method

Retrospective observational study on hospital patient records.

Time Range

Patient data from January 2020 to December 2021, with outcomes observed over three years.

Freshness

Data covers patients from 2020-2021, with study results last updated in April 2026.

Geography

Patients from Zhongshan Hospital, China.